Results from a Phase I study presented Friday at the ASGCT 2024 annual meeting showed that despite a good safety profile, ...

An updated draft of the BIOSECURE Act introduced on Friday would give U.S. drug manufacturers additional leeway for existing ...

Takeda on Monday said it is paying AC Immune $100 million upfront for an option on a Phase Ib/II Alzheimer’s disease ...

The major biopharma players have promised to increase their investments in France to help boost their respective global ...

A pre-planned analysis revealed patients receiving the vibostolimab-Keytruda coformulation in a late-stage trial had a high ...

The race is on to develop therapeutic cancer vaccines that could give immunotherapies an edge, and late-stage trials could ...

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central ...

Amylyx’s recent decision to withdraw its ALS drug Relyvrio from the market highlights an important business decision for ...

With its first-in-class endothelin and angiotensin II receptor antagonist Filspari, Travere Therapeutics is providing a more ...

The FDA is looking at five big decision deadlines in the coming three weeks, including two for a CAR-T therapy and another ...